Literature DB >> 1511535

A review of assay methods for cyclosporin. Clinical implications.

K T Kivistö1.   

Abstract

Cyclosporin is a unique immunosuppressive agent with a narrow therapeutic range. The pharmacokinetics of the drug present substantial within- and between-patient variability and drug interactions can significantly alter blood cyclosporin concentrations. Monitoring of cyclosporin concentrations in blood is an invaluable and essential aid in adjusting dosage to ensure adequate immunosuppression while minimising toxicity. The principal rationale behind therapeutic monitoring of cyclosporin is the fact that the incidence of rejection is higher at low cyclosporin concentrations and toxicity occurs more often at high concentrations. In renal transplant recipients, cyclosporin concentrations help to discriminate between insufficient immunosuppression and cyclosporin-induced nephrotoxicity. There are several methods available, both specific and nonspecific, for the routine measurement of cyclosporin. Radioimmunoassay and fluorescence polarisation immunoassay are most widely employed, while high performance liquid chromatography remains the reference procedure. The allegedly specific immunoassays tend to slightly overestimate the actual blood cyclosporin concentrations. There is a need for assay systems capable of measuring the biological activity of cyclosporin. Cyclosporin concentrations should be determined by a specific method, using whole blood as the sample matrix. The routine monitoring of individual cyclosporin metabolites is not warranted, but characterising the metabolite pattern of cyclosporin by concomitant use of a nonspecific and a specific assay can be clinically useful in patients with cyclosporin-associated toxicity or impaired liver function. In organ transplantation, measurement of blood cyclosporin concentration should be continued periodically as long as the therapy continues, whereas monitoring is only indicated in special circumstances in patients with autoimmune and other nontransplant diseases. The assessment of a 'therapeutic window' for cyclosporin is complicated for several reasons and definite target ranges cannot be given. Cyclosporin concentrations should always be interpreted in conjunction with the recent blood concentration history and other relevant clinical and laboratory data.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1511535     DOI: 10.2165/00003088-199223030-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  147 in total

1.  Cyclosporin: use outside transplantation.

Authors:  A W Thomson; G H Neild
Journal:  BMJ       Date:  1991-01-05

2.  Specific and nonspecific monoclonal 125I-Incstar assays.

Authors:  P Y Wong; J Ma
Journal:  Transplant Proc       Date:  1990-06       Impact factor: 1.066

Review 3.  Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters.

Authors:  B D Kahan
Journal:  Transplantation       Date:  1985-11       Impact factor: 4.939

4.  Minimal low dosage of cyclosporine therapy in renal transplantation by careful monitoring of high-performance liquid chromatography whole blood trough levels.

Authors:  K Uchida; N Yamada; A Orihara; Y Tominaga; Y Tanaka; S Hayashi; T Kondo; K Morozumi; M Satake; N Taira
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

5.  Cyclosporine and metabolites in blood from renal allograft recipients with nephrotoxicity, rejection, or good renal function: comparative high-performance liquid chromatography and monoclonal radioimmunoassay studies.

Authors:  T G Rosano; M A Pell; B M Freed; M T Dybas; N Lempert
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

6.  Monoclonal antibodies for the radioimmunoassay of cyclosporine.

Authors:  J T Marsden; A Johnston; D W Holt
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

7.  Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood.

Authors:  R W Yatscoff; K R Copeland; C J Faraci
Journal:  Clin Chem       Date:  1990-11       Impact factor: 8.327

8.  Cyclosporine blood levels--an evaluation of radioimmunoassay with selective monoclonal or polyclonal antibodies and high-performance liquid chromatography in liver transplant recipients.

Authors:  J M Tredger; C M Steward; R Williams
Journal:  Transplantation       Date:  1988-11       Impact factor: 4.939

9.  A radioreceptor assay for the measurement of cyclosporine activity: a preliminary report.

Authors:  J G Donnelly; S J Soldin
Journal:  Ther Drug Monit       Date:  1989-11       Impact factor: 3.681

10.  Chemiluminescence immunoassay of cyclosporine in whole blood.

Authors:  T V Stabler; A L Siegel
Journal:  Clin Chem       Date:  1990-06       Impact factor: 8.327

View more
  12 in total

Review 1.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

Review 2.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 3.  Prevention of transplant rejection: current treatment guidelines and future developments.

Authors:  N Perico; G Remuzzi
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

Review 4.  Prevention and management of graft-versus-host disease. Practical recommendations.

Authors:  G B Vogelsang; L E Morris
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 6.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

Review 7.  Population pharmacokinetics of cyclosporine in transplant recipients.

Authors:  Kelong Han; Venkateswaran C Pillai; Raman Venkataramanan
Journal:  AAPS J       Date:  2013-06-18       Impact factor: 4.009

8.  Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation.

Authors:  Stefano Federico; Rosa Carrano; Domenico Capone; Antonio Gentile; Giuseppe Palmiero; Vincenzo Basile
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

9.  Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates.

Authors:  S Fanta; S Jönsson; J T Backman; M O Karlsson; K Hoppu
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

Review 10.  Cyclosporin clinical pharmacokinetics.

Authors:  A Fahr
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.